Berenberg analyst Kerry Holford raised the firm’s price target on Eli Lilly to $1,000 from $850 and keeps a Buy rating on the shares. One year on from the firm’s “deep-dive on obesity,” it says the topic continues to dominate meetings with investors. Net-net, the analyst raised the firm’s global obesity market sales forecasts to $150B by 2035 from $125B. It remain buyers of Eli Lilly and Zealand Pharma and retains a Hold rating on Novo Nordisk.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly CFO Anat Ashkenazi Resigns, Gordon Brooks Steps In
- Novo Nordisk (NYSE:NVO) Shares Dip After JAMA Study Results
- Patients more likely to lose weight with Mounjaro than Ozempic, study says
- Morphic downgraded to Market Perform from Outperform at BMO Capital
- M&A News: Eli Lilly Snaps Up Morphic in $3.2B Deal
